Two highly selective BRD4 inhibitors, ZL0420 and ZL0454, were compared to the non-selective pan-BET inhibitors, JQ1 and RVX208 (also called apabetalone), with respect to their ability to reduce chronic airway remodeling induced by TLR3 using a mouse model that mimics recurrent virus-induced asthma exacerbations [33]. The gene discussed is BRD4; the disease is asthma.